Skip to main content
. 2023 Feb 13;15(2):631. doi: 10.3390/pharmaceutics15020631

Figure 4.

Figure 4

In vivo tumor targeting capability of PCLP observed by a multimodal animal imaging system. (A) In vivo fluorescent imaging of HepG2 tumor bearing mice at 6, 10, 24 and 32 h after intravenous injection of PCLP-DiR and LP-DiR. (B) Ex vivo fluorescent imaging of the excised tumors and organs at 24 h post injection of PCLP-DiR and LP-DiR. (C) Region-of-interest analysis of fluorescence intensities from the tumors and organs (n = 3). * p < 0.05.